Psoriatic Arthritis News

Most patients with immune-mediated inflammatory diseases who had weakened responses to a standard vaccine series for COVID-19 mounted a serological response to a third dose, according to data published in Arthritis and Rheumatology.

In patients with early psoriatic arthritis who are naïve to disease-modifying antirheumatic drugs, swollen joints are a better predictor of synovitis than tender joints, according to data published in Rheumatology Advances in Practice.

Patients with autoimmune rheumatic diseases who are undergoing elective hip or knee arthroplasty should maintain their usual doses of methotrexate, leflunomide, hydroxychloroquine, sulfasalazine and apremilast , according to new guidelines.

Real-world patients with psoriatic arthritis who receive secukinumab for 6 months maintain consistent proportions of minimal disease activity and demonstrate improved patient-reported outcomes, according to data.

Patients with psoriatic arthritis treated with bimekizumab demonstrated improvements across joint and skin parameters compared with placebo, according to Phase 3 clinical trial data presented at the EULAR 2022 Congress.

CLEVELAND —In this video from the Medical Dermatology Therapy Update II meeting, Florian Rieder, MD, discusses how a medical home for inflammatory diseases could benefit patients.

CLEVELAND — In this video, M. Elaine Husni, MD, MPH, stressed the importance of taking into consideration the comorbidities of a patient with immune-mediated disease.

CLEVELAND — At the Medical Dermatology Therapy Update II, Andrew Blauvelt, MD, MBA, gave an update on available psoriasis therapies and those on the horizon.

CLEVELAND — It is important to implement a wellness strategy for patients who have immune-mediated inflammatory disease, according to M. Elaine Husni, MD, MPH, of the department of rheumatic and immunologic disease at the Cleveland Clinic.

CLEVELAND — Cassandra Calabrese, DO, emphasized the importance of vaccines for patients with immune-mediated inflammatory diseases at the Medical Dermatology Therapy Update II meeting.